Tempus AI, Inc. (TEM) Stock: Price, Forecast & Analyst Target
Tempus AI, Inc. (TEM) — MoonshotScore 33/100 (Weak band), calculated Nov 18, 2026. Price $63.62 (+0.30%), as of the Nov 18, 2026 trading session; market cap $11.6B. Expected results Feb 23, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 18.20× (cash as of Sep 30, 2026) · expected results Feb 23, 2027
Tempus AI, Inc. · TEM · NASDAQ · Healthcare · Medical - Healthcare Information Services
Research dated 2026-09-13: Tempus AI sells molecular diagnostics and connects the resulting clinical and molecular information to software, research tools, trial matching, and data licensing for clinicians and life-sciences companies. Its prospects depend on whether that linked system can keep expanding revenue while moving from persistent operating losses and uneven cash use toward durable self-funding.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Tempus AI (TEM)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fragile balance sheet and a full valuation; the market is already moving on it. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Fragile; Valuation: Full; Growth Durability: Growing; Momentum: Surging.
- EPS beat 7 of the last 8 reports
- Altman Z 2.86 · Piotroski F 2
- ROE -40.9% · ROA -7.7% · current ratio 2.61 · earnings yield -1.6% · free-cash-flow yield -1.3%
Holding back: balance-sheet strain
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 33 | Weak | |
| 33 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $63.62 | |
| Change on the day | +0.30% | |
| 52-week range | $40.77–$104.32 | |
| Market capitalisation | $11.6B | — |
| Price / earnings (trailing) | -143.61 | |
| Shares traded on the day | 5.35M | |
| Beta (volatility vs the S&P 500) | 3.61 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Tempus AI (TEM): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Tempus AI (TEM), and what does it report?
Short answer · as of
A healthcare-information label can suggest a software vendor, but Tempus is also a laboratory diagnostics business.
Research dated 2026-09-13.
Its assays generate molecular results, while Hub, Lens, Insights, Trials, Next, and Algos extend those results into clinical workflow, research, data licensing, trial matching, and algorithm-based diagnostics.
Reported revenue therefore blends testing activity with software- and data-oriented offerings. Diagnostics supplies most of the disclosed revenue, making test demand central even though the broader platform reaches physicians, researchers, and life-sciences collaborators.
What do the latest results show for Tempus AI (TEM)?
Research dated 2026-09-13.
Revenue rebounded in the latest period and gross profit rose with it. The operating loss narrowed, while the reported net result crossed into profit after a substantial loss in the preceding period.
That profit does not yet establish a durable earnings model. Research and development together with selling and administrative expense remained above gross profit, operating cash flow was still negative, and recent cash generation has moved sharply between inflow and outflow even as reported revenue has generally cleared expectations.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $411.54M Sep 30, 2026
- Latest quarter · R&D
- $91.71M Sep 30, 2026
- Latest quarter · SG&A
- $231.86M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- −$56.86M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $411.54M | $91.71M | $231.86M | −$56.86M |
| Jun 30, 2026 | $382.49M | $96.57M | $225.84M | −$75.91M |
| Mar 31, 2026 | $348.12M | $94.16M | $212.59M | −$84.71M |
| Dec 31, 2025 | $367.21M | $90.62M | $192.20M | −$61.41M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $411.54M Nov 2, 2026
- Latest report · revenue estimate
- $409.39M Nov 2, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 2, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 2, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 2, 2026 | $411.54M | $409.39M | $0.0700 | −$0.0937 |
| Jul 30, 2026 | $382.49M | $379.69M | −$0.0400 | −$0.1428 |
| May 5, 2026 | $348.12M | $345.44M | −$0.1300 | −$0.2100 |
| Feb 24, 2026 | $367.21M | $362.55M | −$0.0400 | −$0.0438 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $334M | -$80M | -$0.46 (diluted) |
| Q4 FY2025 | $367M | -$54M | -$0.30 (diluted) |
| Q1 FY2026 | $348M | -$126M | -$0.71 (diluted) |
| Q2 FY2026 | $382M | $6M | $0.03 (diluted) |
What are the financial strengths and risks for Tempus AI (TEM)?
Short answer
Cash and short-term investments were $637.35M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $9.22M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Cash and investments provide meaningful room against the recent pace of operating and capital spending, and liquidity increased from the preceding period. The runway estimate indicates that current resources can absorb continued burn for a substantial interval if the recent usage rate holds.
Debt nevertheless exceeds cash and investments, so Tempus does not have a net-cash balance sheet. The main financial risk is that diagnostics, licensing, and research demand slow while research and commercial spending remain elevated; that combination would prolong operating losses and consume liquidity before the platform becomes self-funding.
Data-derived red flags
- Negative return on equity (-40.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $9.22M Sep 30, 2026
- Previous quarter · operating cash flow
- −$7.52M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $9.22M | −$14.76M |
| Jun 30, 2026 | −$7.52M | −$11.09M |
| Mar 31, 2026 | −$73.28M | −$10.07M |
| Dec 31, 2025 | −$36.79M | −$6.34M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Tempus AI (TEM)?
Short answer · as of
The next earnings report is expected on Feb 23, 2027.
Research dated 2026-09-13.
Revenue, operating loss, and operating cash flow now need to improve together. Continued sales growth would be less persuasive if research and commercial spending keep gross profit from reaching the operating line or if cash use widens again.
Watch whether the upcoming result extends the pattern of revenue exceeding expectations, whether operating cash flow stays near balance, and whether liquidity improves without a matching rise in debt. Longer-range estimates assume continued revenue expansion and eventual positive earnings, making operating leverage the practical test of that path.
How does Tempus AI compare with its peers?
Short answer
Tempus AI's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Compared with a laboratory business focused only on processing tests, Tempus carries diagnostic results into physician workflow, research applications, trial matching, and licensed data. Compared with healthcare software that sits apart from testing, it also produces molecular and pathology information through its own diagnostic capabilities.
The distinctive mechanism is the feedback loop between assays, multimodal clinical information, and applications built for clinicians and life-sciences customers. That breadth creates more routes to revenue, but diagnostics remains the largest disclosed component, so the software and data narrative cannot be evaluated separately from laboratory execution.
| Company | Price | Market value | Score |
|---|---|---|---|
| $114.53 Nov 18, 2026 | $9.31B | 97 5-pillar Nov 18, 2026 | |
| $162.86 Nov 18, 2026 | $16.5B | 95 5-pillar Nov 18, 2026 | |
| $30.67 Nov 18, 2026 | $5.47B | 95 5-pillar Nov 18, 2026 | |
| $36.16 Nov 18, 2026 | $2.66B | 95 5-pillar Nov 18, 2026 | |
| $646.87 Nov 18, 2026 | $18.1B | 92 5-pillar Nov 18, 2026 | |
| $262.92 Nov 19, 2026 | $42.6B | 92 5-pillar Nov 18, 2026 | |
| $65.62 Nov 19, 2026 | $32.5B | 91 5-pillar Nov 18, 2026 | |
| $97.31 Nov 18, 2026 | $8.05B | 90 5-pillar Nov 18, 2026 | |
| $68.34 Nov 18, 2026 | $13.6B | 87 5-pillar Nov 18, 2026 | |
| $30.32 Nov 18, 2026 | $12.7B | 84 5-pillar Nov 18, 2026 | |
| $24.60 Nov 18, 2026 | $3.14B | 79 5-pillar Nov 18, 2026 | |
| $83.66 Nov 18, 2026 | $37.8B | 74 5-pillar Nov 18, 2026 | |
| Tempus AI (TEM) — this page | $63.62 | $11.6B | 33 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $50.00 – $100.00
- Consensus target
- $77.83
- Median target
- $78.00
Consensus record · Captured .
Measured against a quoted price of $63.62 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 2, 2026
- Transactions
- 153
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 148
- Other transactions
- 5
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 62.6% Period end Sep 30, 2026
- Previous quarter · ownership
- 62.3% Prior to period end Sep 30, 2026
- Reporting holders
- 624 Period end Sep 30, 2026
- Previous quarter · holders
- 543 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 9,624,840 |
| Ark Investment Management LLC | 9,357,545 |
| Baillie Gifford & Co | 6,911,932 |
| Softbank Group Corp. | 5,405,406 |
| Jpmorgan Chase & Co | 5,326,447 |
Tracked investors
Which of the 16 named investors we follow held TEM in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| ARK Invest | Cathie Wood | Q3 2026 | 4.41% | $766.38M | Trimmed −6.6% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Tempus AI (TEM)?
- Natera vs. Tempus AI: Which Blood Test Pioneer Has the Better Stock Buy for 2027?
- What's Going To Happen With Tempus AI Stock Soon?
- AI in Clinical Trials - Global Strategic Business Report 2026: Secure Share of a US$4.1 Billion Market by 2032 with IQVIA, Microsoft, Tempus AI, and Saama
- AstraZeneca, Tempus AI Extend Services Agreement Through 2031
TEM Healthcare Stock FAQ
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How do Tempus xT and xR connect with Hub?
The assays generate broad molecular information, while Hub gives healthcare providers an end-to-end clinical application for ordering and using diagnostic tests. Together they link laboratory work with the clinician’s desktop rather than treating the test as a standalone product.
What do Tempus Lens and Insights sell to life-sciences customers?
Lens supports life-sciences research, while Insights licenses linked, de-identified clinical, molecular, and imaging information. These offerings commercialize the company’s data and analytical capabilities beyond patient testing.
Why does Diagnostics shape Tempus AI’s reported business?
Diagnostics contributes most of the disclosed segment revenue, so assay demand remains the clearest reported measure of commercial scale. The applications and data businesses broaden the model, but they do not make Tempus a pure software company.
What does the recent Tempus insider selling pattern establish?
The disclosed activity shows sales by several insiders and no purchases during the measured window. Transaction records establish what occurred, but they do not establish why an insider sold.
What is the TEM stock price today?
The last price recorded for Tempus AI, Inc. (TEM), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the TEM price target?
The analyst consensus price target for Tempus AI, Inc. (TEM), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 80 figures on this page — 1 from SEC filings and earnings calls, 71 from Financial Modeling Prep (FMP), 4 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold TEM
Funds in our ETF coverage that list TEM among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| ARK Innovation ETF (ARKK) | 6.16% |